



Adult vaccination in practice with AREXVY & SHINGRIX

Making every risk
conversation personal



YOU'RE INVITED TO ATTEND A VIRTUAL WEBINAR

For Australian Healthcare Professionals



When



Where



RSVP

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS
VACCINE RECOMBINANT, ADJUVANTED)



SHINGRIX

Recombinant Varicella Zoster Virus
glycoprotein E antigen (AS01B adjuvanted
vaccine)

You are invited to an upcoming educational webinar to explore the burden of RSV disease, shingles and preventative options in older adults. To register for this event, please scan the QR code or contact your GSK sales representative.



Learning objectives

RSV learning objectives

- Identify patients who are eligible for RSV vaccination
- Educate patients on their individual risk of RSV disease and the efficacy and safety profile of AREXVY
- Vaccinate with confidence by learning practical steps to administer AREXVY in everyday practice

Shingles learning objectives

- Understand the risk and impact of shingles
- Recognise the importance of vaccinating adults ≥ 50 years of age
- Describe the clinical profile of SHINGRIX
- Develop strategies for implementing SHINGRIX discussions within your practice

CODE

Scan to register or visit:

To register directly with your GSK Representative or
for questions regarding this meeting, please contact:



Speakers



Ms Philippa Holland

Ms Philippa Holland has been the Immunisation Coordinator at the City of Melbourne since 2015, overseeing 'whole of life' immunisation services which immunise over 10,000 people each year. She has a particular interest in improving access to immunisation and addressing barriers to vaccination. Philippa partnered with the Murdoch Children's Research Institute to co-design the Migration Immunisation Access (MIA) Project, which received the GSK Immunisation Award in 2020. She is also a tutor with the Australian College of Nursing, supporting nurses and pharmacists to become authorised immunisation providers. Her previous experience includes roles as an Immunisation Educator, clinical research coordinator in vaccine trials, and practice nurse specialising in travel immunisation in London.



Dr Rodney Pearce

Dr Pearce trained in Adelaide and worked at the RAH, QEH and Modbury Hospitals before starting work in General Practice. Dr Pearce was president of the AMA (SA) 1998-2000, GP Nationally Elected Representative on the Federal AMA and Chair of the AMA Council of General Practice for 3 terms from 2004-2010. He is a fellow of the AMA and received the AMA (SA) Presidents award in 2008. In 2008, he was appointed by the then Health Minister, The Hon. Nicola Roxon to the External Reference Group to develop Australia's National Primary Health Care Strategy for the national health reforms and was instrumental in Beulah Park and Athelstone Clinics becoming the first in South Australia to train young doctors in their postgraduate (Intern) years and prevocational years (PGPPP) in the community. He continues to be an active supervisor to GP registrars through the regional training program. On Australia Day 2012, Dr Pearce was admitted to the Order of Australia (AM) for service to medicine as a general practitioner, through contributions to national medical organisations, and to education. Today Dr Pearce continues to hold the position of Deputy Chair on the Board of the Immunisation Coalition as well as positions on several other boards.

Agenda

Indication: AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults ≥ 60 years of age and in adults 50–59 years of age who are at increased risk for RSV disease.¹
Dosing and administration: AREXVY is administered as a single, reconstituted dose of 0.5 mL by intramuscular injection. The need for revaccination has not been established.¹
Safety: Very common adverse events ($\geq 10\%$) are headache, myalgia, arthralgia, injection site pain and fatigue. Common adverse events ($\geq 1\%$) are injection site erythema, injection site swelling, fever, chills and rhinorrhoea (not a complete list; see full PI).¹

PBS Information: AREXVY is listed on the National Immunisation Program (NIP) for all individuals aged ≥ 75 years and Aboriginal and Torres Strait Islander adults aged ≥ 60 years. Refer to NIP schedule or your State or Territory Health department.



PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.

Product Information can be accessed by scanning to QR code or at www.gsk.com.au/arexvy

Indication: SHINGRIX is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in: adults 50 years of age or older, and in adults 18 years of age or older at increased risk of HZ.² **Contraindication:** Hypersensitivity to the active substances or to any component of the vaccine.² **Safety:** In pivotal trials, very common ($\geq 10\%$) solicited local adverse reactions and solicited general adverse events were pain, redness, and swelling at the injection site; and myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms, respectively.²

References: 1. AREXVY Product Information. 2. SHINGRIX Product Information.
Abbreviations: HZ, herpes zoster; RSV, respiratory syncytial virus

PBS Information: SHINGRIX is listed on the National Immunisation Program (NIP) for Aboriginal and Torres Strait Islander adults aged ≥ 50 years, for all individuals aged ≥ 65 years and for adults aged ≥ 18 years with some immunocompromising medical risk conditions. Refer to NIP schedule or your State or Territory Health department.



PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.

Product Information can be accessed by scanning to QR code or at www.gsk.com.au/shingrix

▼ These medicinal products are subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

For Australian healthcare professionals. This educational activity was initiated, developed and organised by GSK. This is an educational event for your professional development. Therefore, accompanying persons such as family members or friends are not invited to attend. We intend to record this session and to distribute the recording to Healthcare Professionals. Accordingly, your personal information and attendance at the meeting may form part of the recording. Please let us know if you have any concerns. We, GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding 'Adult vaccination in practice with AREXVY & SHINGRIX.' We may disclose your personal information to third parties we use in the ordinary operations of our business, including our affiliates and third parties located overseas. If we do not collect your personal information, we may be unable to provide you with all of our services. Our privacy policy can be found at <https://privacy.gsk.com/en-au/privacy-notice/general/> and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd, PO Box 18095, Melbourne, Victoria, 8003. To opt-out of receiving further communications from GSK, please unsubscribe. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd, Melbourne, VIC.

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS
VACCINE RECOMBINANT, ADJUVANTED)

SHINGRIX
Recombinant Varicella Zoster Virus
glycoprotein E antigen (AS01B adjuvanted
vaccine)

GSK